Table of Content

1. Introduction
1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency and Limitation
1.4. Key Stakeholders

2. Research Methodology
2.1. Research Approach
2.2. Process of Data Collection and Validation
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders of The Industry
2.3. Market Sizing and forecast
2.3.1. Market Size Estimation Approach
2.3.2. Growth Forecast Approach
2.3.3. Market Share Analysis
2.4. Assumptions for the Study

3. Executive Summary

4. Market Insights
4.1. Overview
4.2. Factors Affecting Market Growth
4.2.1. Impact Analysis of Market Dynamics
4.2.2. Factor Analysis
4.3. Use Cases
4.3.1. Use Case A
4.3.2. Use Case B
4.3.3. Use Case C
4.3.4. Use Case D
4.3.5. Use Case E
4.4. Porter’s Five Forces Analysis
4.4.1. Bargaining Power of Buyers
4.4.2. Bargaining Power of Suppliers
4.4.3. Threat of Substitutes
4.4.4. Threat of New Entrants
4.4.5. Degree of Competition
4.5. Next–Generation Sequencing (NGS) Informatics Market: Regulatory Analysis

5. Next Generation Sequencing (NGS) Informatics Market Assessment–by Offering
5.1. Overview
5.2. Software
5.2.1. By Type
5.2.1.1. Data Analysis Software
5.2.1.2. Data Interpretation and Reporting Tools
5.2.1.3. Data Storage and Computing Tools
5.2.1.4. Laboratory Information Management Systems (LIMS)
5.2.2. By Deployment Mode
5.2.2.1. Web and Cloud–Based
5.2.2.2. On-Premise
5.3. NGS Informatics Services

6. Next–Generation Sequencing (NGS) Informatics Market Assessment–by Application
6.1. Overview
6.2. Drug Discovery
6.3. Disease Diagnoses
6.4. Biomarker Discovery
6.5. Precision Medicine
6.6. Agriculture and Animal Research

7. Next–Generation Sequencing (NGS) Informatics Market Assessment–by End User
7.1. Overview
7.2. Pharmaceutical & Biotechnology Companies
7.3. Hospitals & Diagnostic Laboratories
7.4. Academic & Research Institutes
7.5. Other End Users

8. Next–Generation Sequencing Informatics (NGS) Market Assessment?by Geography
8.1. Overview
8.2. North America
8.2.1. U.S.
8.2.2. Canada
8.3. Europe
8.3.1. Germany
8.3.2. France
8.3.3. U.K.
8.3.4. Italy
8.3.5. Spain
8.3.6. Rest of Europe (RoE)
8.4. Asia–Pacific
8.4.1. China
8.4.2. Japan
8.4.3. India
8.4.4. Rest of Asia–Pacific (RoAPAC)
8.5. Latin America
8.5.1. Brazil
8.5.2. Mexico
8.5.3. Rest of Latin America
8.6. Middle East & Africa

9. Competition Analysis
9.1. Overview
9.2. Key Growth Strategies
9.3. Competitive Benchmarking
9.4. Market Share Analysis (2022)
9.4.1. Illumina, Inc. (U.S.)
9.4.2. Qiagen N.V. (Netherlands)
9.4.3. Thermo Fisher Scientific Inc. (U.S.)
9.4.4. Agilent Technologies, Inc. (U.S.)
9.4.5. F. Hoffmann–La Roche Ltd (Switzerland)
9.5. Vendor Dashboard
9.5.1. Industry Leaders
9.5.2. Market Differentiators
9.5.3. Vanguards
9.5.4. Emerging Companies

10. Company Profiles (Business Overview, Financial Overview, Product Portfolio, SWOT Analysis of Top 5 Companies, and Strategic Developments)
10.1. Thermo Fisher Scientific, Inc.
10.2. Illumina, Inc.
10.3. QIAGEN N.V.
10.4. F. Hoffmann–La Roche Ltd
10.5. Agilent Technologies, Inc.
10.6. DNAnexus, Inc.
10.7. Partek Incorporated
10.8. Fabric Genomics, Inc.
10.9. DNASTAR, Inc.
10.10. Sapio Sciences, LLC

11. Appendix
11.1. Available Customization
11.2. Related Reports



List of Figures

List of Figures
Figure 1 Research Process
Figure 2 Secondary Sources Referenced for This Study
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply–Side & Demand–Side)
Figure 6 Market Sizing and Growth Forecast Approach
Figure 7 Global NGS Informatics Market, by Offering , 2023 VS. 2030 (USD Million)
Figure 8 Global NGS Informatics Software Market, by Deployment Mode, 2023 VS. 2030 (USD Million)
Figure 9 Global NGS Informatics Market, by Application, 2023 VS. 2030 (USD Million)
Figure 10 Global NGS Informatics Market, by End User, 2023 VS. 2030 (USD Million)
Figure 11 Global NGS Informatics Market Shares, by Geography, 2023
Figure 12 Pharmaceutical R&D Expenditures in the U.S., Europe, and China, 2010 VS. 2019 VS. 2020 (USD Million)
Figure 13 Global Pharmaceutical R&D Expenditure, 2012–2026 (USD Billion)
Figure 14 Porter’s Five Forces Analysis
Figure 15 Global NGS Informatics Market, by offering , 2023 VS. 2030 (USD Million)
Figure 16 Global NGS Informatics Software Market, by Deployment Mode, 2023 VS. 2030 (USD Million)
Figure 17 Global NGS Informatics Market, by Application, 2023 VS. 2030 (USD Million)
Figure 18 Estimated Number of New Cancer Cases (In Million)
Figure 19 Percentage of FDA Approvals for Personalized Medicine, 2015–2021
Figure 20 Global NGS Informatics Market, by End User, 2023 VS. 2030 (USD Million)
Figure 21 Global Pharmaceutical R&D Spending, 2014–2028 (USD Billion)
Figure 22 Global NGS Informatics Market, by Geography, 2023 VS. 2030 (USD Million)
Figure 23 North America: NGS Informatics Market Snapshot
Figure 24 U.S.: Pharmaceutical R&D Expenditure, 2014–2021 (USD Billion)
Figure 25 Europe: Pharmaceutical Industry R&D Expenditure (2000–2021)
Figure 26 Europe: NGS Informatics Market Snapshot
Figure 27 Italy: Number of Biotechnology Firms, 2010–2021
Figure 28 RoE: Pharmaceutical R&D Expenditure, 2020
Figure 29 Asia–Pacific: NGS Informatics Market Snapshot
Figure 30 Latin America: NGS Informatics Market Snapshot
Figure 31 Key Growth Strategies Adopted by Leading Players (2020–2023)
Figure 32 Next Generation Sequencing (NGS) Informatics Market: Competitive Benchmarking, by Offering
Figure 33 Next Generation Sequencing (NGS) Informatics Market: Competitive Benchmarking, by Region
Figure 34 Global Next Generation Sequencing (NGS) Informatics Market Share Analysis, by Key Players, 2022 (%)
Figure 35 Vendor Dashboard: Next Generation Sequencing (NGS) Informatics Market
Figure 36 Thermo Fisher Scientific, Inc.: Financial Overview (2022)
Figure 37 Illumina, Inc.: Financial Overview (2022)
Figure 38 QIAGEN N.V.: Financial Overview (2022)
Figure 39 F. Hoffmann–La Roche Ltd: Financial Overview (2022)
Figure 40 Agilent Technologies, Inc.: Financial Overview (2022)